🇺🇸 FDA
Patent

US 7541034

Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors

granted A61KA61K38/00A61K47/6849

Quick answer

US patent 7541034 (Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors) held by The United States of America, as represented by the Department of Health and Human Services expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K38/00, A61K47/6849, A61P, A61P35/00